Product image of Norgestimaat/Ethinylestradiol Xiromed (Ethinylestradiol, Norgestimate) supplied by GNH India

Norgestimaat/Ethinylestradiol Xiromed

Active Ingredient:
Ethinylestradiol, Norgestimate
Origin:
EU

Norgestimaat/Ethinylestradiol Xiromed (Ethinylestradiol, Norgestimate)

Ethinylestradiol, the active ingredient in Norgestimaat/Ethinylestradiol Xiromed, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age. Norgestimate, the second active ingredient, works together with ethinylestradiol to provide reliable hormonal birth control.

GNH India supplies Norgestimaat/Ethinylestradiol Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medical Valley Invest Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Norgestimaat/Ethinylestradiol Xiromed is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

  • Contraception: prevents pregnancy by suppressing ovulation and altering cervical mucus.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
  • Reduction of functional ovarian cysts: decreases the formation of benign ovarian cysts.

How It Works

  • Ethinylestradiol and norgestimate bind to estrogen and progestin receptors, respectively, suppressing the hypothalamic‑pituitary‑gonadal axis. This inhibition reduces the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), preventing follicular development and ovulation. The progestin component also thickens cervical mucus and modifies the endometrial lining, creating an environment unsuitable for sperm penetration and implantation.

Side Effects

Norgestimaat/Ethinylestradiol Xiromed may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: swelling or discomfort of the breasts.
  • Weight gain: modest increase in body weight.
  • Mood changes: irritability or emotional fluctuations.
  • Spotting: light bleeding between periods.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in deep veins.
  • Pulmonary embolism: clot migration to the lungs.
  • Stroke: interruption of cerebral blood flow.
  • Myocardial infarction: heart attack due to coronary blockage.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Liver dysfunction: jaundice or abnormal liver enzymes.

Precautions & Warnings

Before prescribing Norgestimaat/Ethinylestradiol Xiromed, clinicians should evaluate patient history and risk factors.

  • Contraindications: Do not use in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease.
  • Smoking: Avoid in women over 35 who smoke, due to increased cardiovascular risk.
  • Medical history: Assess for hypertension, diabetes, or migraine with aura.
  • Medication adherence: Take the tablet at the same time each day to maintain efficacy.
  • Store at ambient temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Norgestimaat/Ethinylestradiol Xiromed can interact with several medicines, affecting its effectiveness or safety.

Major Interactions (Avoid)

  • Antiepileptics (carbamazepine, phenytoin): reduce contraceptive efficacy.
  • Antibiotics (rifampin, griseofulvin): may lower hormone levels.
  • St. John’s wort: decreases contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

  • Antifungals (ketoconazole): may increase hormone concentrations.
  • Antidepressants (SSRIs): may enhance mood‑related side effects.
  • Diuretics (spironolactone): may affect fluid balance and blood pressure.

Frequently Asked Questions

Norgestimaat/Ethinylestradiol Xiromed is a combined oral contraceptive containing ethinylestradiol and norgestimate. It is prescribed to prevent pregnancy in women of reproductive age by inhibiting ovulation and modifying cervical mucus and the endometrial lining.

Ethinylestradiol is a synthetic estrogen that binds to estrogen receptors, providing negative feedback to the hypothalamus and pituitary gland. This feedback reduces the secretion of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby suppressing ovulation and contributing to the contraceptive effect.

The specific dosing regimen is determined by the prescribing clinician. Typically, the product is taken as one tablet daily for 21 consecutive days followed by a hormone‑free interval, but the exact schedule should follow the prescriber’s instructions.

The medication is contraindicated during pregnancy and should be stopped if pregnancy occurs. Limited safety data exist for breastfeeding; most guidelines advise caution and suggest alternative contraception for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Norgestimaat/Ethinylestradiol Xiromed contains the progestin norgestimate, which is associated with a lower incidence of androgenic side effects such as acne compared with some older progestins. Its efficacy in preventing pregnancy is comparable to other FDA‑approved combined pills, while the side‑effect profile may differ slightly based on individual tolerance.

Store the tablets at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally with water. For optimal effectiveness, it should be taken at the same time each day, preferably with or without food, as directed by the healthcare provider.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe reactions can involve severe allergic responses and liver dysfunction. Patients should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe headache, or jaundice.

Women with a history of blood‑clotting disorders, estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or who are pregnant or breastfeeding should avoid this product. Additionally, smokers over 35 years of age are advised not to use combined oral contraceptives due to increased cardiovascular risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Norgestimate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT